YS ON 001

Drug Profile

YS ON 001

Alternative Names: Polyinosinic-polycytidylic acid/inactivated rabies virus; Yivyka™; YS-ON-001

Latest Information Update: 03 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Yisheng Biopharma
  • Class Antineoplastics; Cancer vaccines
  • Mechanism of Action B cell stimulants; Cytokine stimulants; Dendritic cell stimulants; Immunomodulators; Macrophage modulators; Natural killer cell stimulants; Regulatory T lymphocyte inhibitors; Th1 cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatocellular carcinoma; Pancreatic cancer
  • New Molecular Entity No

Highest Development Phases

  • Registered Solid tumours
  • Clinical Phase Unknown Cancer

Most Recent Events

  • 19 Jul 2018 Registered for Solid tumours in Cambodia (IM)
  • 26 Feb 2018 YS ON 001 receives Orphan Drug status for Pancreatic cancer in USA
  • 30 Aug 2017 Pharmacodynamics data from preclinical studies in Solid tumours released by Yisheng Biopharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top